Entrada Therapeutics

6 Tide Street
United States

2023 Best Places to Work
Featured Employer
NextGen Class of 2020
Show jobs for this employer

About Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).

Stock Symbol: TRDA
Stock Exchange: NASDAQ



“Most targets for drug development are actually intracellular,” says Dipal Doshi, President and CEO of Entrada Therapeutics. “Think about how many drugs can be made that can help patients if we can figure out a way to effectively get inside the cell…that’s why Entrada’s important.”

38 articles about Entrada Therapeutics